Skip to main content

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Completed · Phase 3 · NCT05929079

Conditions: Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea

At a glance

Research payments reported, 2025
$5.5M
U.S. investigators named
50
Sites paid
48
Planned or actual enrollment
1,152

About the trial

Sponsor
Eli Lilly and Company
Tested
Retatrutide (drug), Placebo (drug)
Dates
Started 2023-07-11; completion 2026-06-16
Results posted
Not yet

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

From ClinicalTrials.gov, last updated 2026-07-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $5.5M in research payments for this study in 2025 (105 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Clinical Research of Broward County DBA Clinical Research Center of Florida $425,787
  • Valley Clinical Trials Inc $326,928
  • Renstar Inc $306,370
  • Velocity Clinical Research Inc $282,114
  • Teradan Clinical Trials LLC $251,728
  • Lillestol Research LLC $247,200
  • Sociedad Espanola De Medicina De La Adolescencia $228,938
  • Palm Beach Research Center $215,346
  • Cti Holdings Inc DBA Community Research Management Associates Inc $215,167
  • Studymetrix Research LLC $207,799
  • Quantum Clinical of Dade County, DBA Quantum Clinical Trials $199,358
  • Compass Point Research Inc $188,050
  • Futuresearch Trials of Neurology LP $180,017
  • Las Vegas Medical Research LLC $177,830
  • Tribe Clinical Research LLC $165,119
  • Northwest Clinical Research Center $154,073
  • Advanced Research Inc $144,163
  • Clinical Site PArtners LLC $134,781
  • Therafirst Medical Centers Inc $132,046
  • Medvadis Research Corp LLC $118,175
  • Cr Services Acquisition US LLC $117,414
  • David Fitzpatrick MD DBA E West Med Rsrch $108,311
  • Chase Medical Research LLC $106,226
  • Preferred Primary Care Physicians Inc $103,128
  • Carteret Medical Group LLC $102,760
  • Wrightsville Family Practice $95,187
  • Pinnacle Research Group LLC $88,211
  • Jacksonville Center for Clinical Research $69,974
  • Intrepid Research LLC $65,559
  • Flourish Research Acquisition LLC $50,886
  • Mid Hudson Medical Research PLLC $46,398
  • Baptist Health $44,886
  • Dr Dennis M Lacey $41,492
  • Monroe Biomedical Research $35,306
  • Francisco Badar MD Inc $31,075
  • Cullman Clinical Trials $26,755
  • $3,799
  • Dallas Diabetes and Endo Research Center PA $2,406
  • Mehrdad Kevin Ariani MD $1,811
  • Cleveland Clinic, OH $1,768
  • Clinical Research Center of Florida $1,285
  • Advanced Research Institute $1,148
  • Mountain View Clinical Research Inc $1,103
  • Columbus Clinical Research Inc $752
  • Future Search Trials of Dallas LP $570
  • Excel Medical Clinical Trials, LLC $500
  • Care Access Research LLC $341
  • Andrew J Lewin Med DBA National Rsrch Institute $105
  • Cti-Crc $15

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.